Ana-Maria de Roda Husman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana-Maria de Roda Husman has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Frank Miedema
Department Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
2 shared publicationsFrank de Wolf
Department Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
2 shared publicationsHanneke Schuitemaker
2 shared publicationsA. Wisman
G. B. A. Wisman and A. G. J. van der Zee, Department of Gynaecology and Obstetrics, Academic Hospital Groningen, University of Groningen, Groningen, Netherlands
1 shared publicationAna-Maria de Roda Husman
K. C. Wolthers, S. A. Otto, A.-M. de Roda Husman, N. Schaft, L. Meyaard, Department of Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology of the University of Amsterdam, Amsterdam, Netherlands
1 shared publicationAte G. J. van der Zee
G. B. A. Wisman and A. G. J. van der Zee, Department of Gynaecology and Obstetrics, Academic Hospital Groningen, University of Groningen, Groningen, Netherlands
1 shared publication
Latest Publications
- 1 June 1998
- Published by Elsevier in Trends in Microbiology
- Vol. 6 (6) , 244-249
Chemokine receptors and the clinical course of HIV-1 infection
- 1 June 1998
- Published by Elsevier in Trends in Microbiology
- Vol. 6 (6) , 244-249
Chemokine receptors and the clinical course of HIV-1 infection
- 1 May 1998
- Published by Wiley in European Journal of Immunology
- Vol. 28 (5) , 1701-1707
Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97
CD97 is an activation-induced antigen on leukocytes which belongs to a new group of seven-span transmembrane (7-TM) molecules, designated EGF-TM7 family. Family members, including EMR1 and F4/80, are characterized by an extended extracellular region with several N-terminal epidermal growth factor-like (EGF) domains. Alternative splicing of CD97 results in isoforms possessing either three (EGF1, 2, 5), four (EGF1, 2, 3, 5) or five EGF domains (EGF1, 2, 3, 4, 5). We recently identified decay accelerating factor (DAF, CD55), a regulatory protein of the complement cascade, as a cellular ligand of the smallest isoform. Employing mutants of CD97(EGF1, 2, 5) in which the EGF domains have been systematically deleted, we here demonstrate the necessity of at least three tandemly linked EGF domains for the interaction with CD55. Consistent with the involvement of different EGF domains, monoclonal antibodies directed against the first EGF domain as well as the removal of Ca2+ , for which binding sites exist in the second and fifth EGF domain, blocked binding to CD55. Compared to CD97(EGF1, 2,5) the larger isoforms CD97(EGF1, 2, 3, 5) and CD97(EGF1, 2, 3, 4, 5) have a significantly lower affinity for CD55. Thus, alternative splicing may regulate the ligand specificity of CD97 and probably other members of the EGF-TM7 family.
- 1 May 1998
- Published by Wiley in European Journal of Immunology
- Vol. 28 (5) , 1701-1707
Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97
CD97 is an activation-induced antigen on leukocytes which belongs to a new group of seven-span transmembrane (7-TM) molecules, designated EGF-TM7 family. Family members, including EMR1 and F4/80, are characterized by an extended extracellular region with several N-terminal epidermal growth factor-like (EGF) domains. Alternative splicing of CD97 results in isoforms possessing either three (EGF1, 2, 5), four (EGF1, 2, 3, 5) or five EGF domains (EGF1, 2, 3, 4, 5). We recently identified decay accelerating factor (DAF, CD55), a regulatory protein of the complement cascade, as a cellular ligand of the smallest isoform. Employing mutants of CD97(EGF1, 2, 5) in which the EGF domains have been systematically deleted, we here demonstrate the necessity of at least three tandemly linked EGF domains for the interaction with CD55. Consistent with the involvement of different EGF domains, monoclonal antibodies directed against the first EGF domain as well as the removal of Ca2+ , for which binding sites exist in the second and fifth EGF domain, blocked binding to CD55. Compared to CD97(EGF1, 2,5) the larger isoforms CD97(EGF1, 2, 3, 5) and CD97(EGF1, 2, 3, 4, 5) have a significantly lower affinity for CD55. Thus, alternative splicing may regulate the ligand specificity of CD97 and probably other members of the EGF-TM7 family.
- 1 June 1997
- Published by Elsevier in Immunology Letters
- Vol. 57 (1-3) , 125-130
Kinetics of immune functions and virus replication during HIV-1 infection
- 1 June 1997
- Published by Elsevier in Immunology Letters
- Vol. 57 (1-3) , 125-130
Kinetics of immune functions and virus replication during HIV-1 infection
- 29 November 1996
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 274 (5292) , 1543-1547
T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4 + T Cell Turnover
Progression to acquired immunodeficiency syndrome (AIDS) has been related to exhaustion of the regenerative capacity of the immune system resulting from high T cell turnover. Analysis of telomeric terminal restriction fragment (TRF) length, a marker for cellular replicative history, showed that CD8 + T cell TRF length decreased but CD4 + T cell TRF length was stable during the course of human immunodeficiency virus type-1 (HIV-1) infection, which was not explained by differential telomerase activity. This observation provides evidence that turnover in the course of HIV-1 infection can be increased considerably in CD8 + T cells, but not in CD4 + T cells. These results are compatible with CD4 + T cell decline in HIV-1 infection caused by interference with cell renewal.
- 29 November 1996
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 274 (5292) , 1543-1547
T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4 + T Cell Turnover
Progression to acquired immunodeficiency syndrome (AIDS) has been related to exhaustion of the regenerative capacity of the immune system resulting from high T cell turnover. Analysis of telomeric terminal restriction fragment (TRF) length, a marker for cellular replicative history, showed that CD8 + T cell TRF length decreased but CD4 + T cell TRF length was stable during the course of human immunodeficiency virus type-1 (HIV-1) infection, which was not explained by differential telomerase activity. This observation provides evidence that turnover in the course of HIV-1 infection can be increased considerably in CD8 + T cells, but not in CD4 + T cells. These results are compatible with CD4 + T cell decline in HIV-1 infection caused by interference with cell renewal.